Vericel Corp (VCEL) Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced therapies for sports medicine (MACI) and severe burn care (Epicel, NexoBrid). The company operates in a single reportable segment and is transitioning its primary MACI manufacturing to a new facility in Burlington, Massachusetts, which received FDA approval in March 2026.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenue | $77,457 | $63,240 | $145,882 | $115,838 |
| Gross Profit | $56,402 | $46,613 | $105,668 | $82,886 |
| Gross Margin | 72.8% | 73.7% | 72.4% | 71.6% |
| Operating Income (Loss) | $434 | $(2,029) | $(7,630) | $(14,821) |
| Net Income (Loss) | $2,206 | $(553) | $(4,096) | $(11,799) |
| Diluted EPS | $0.04 | $(0.01) | $(0.08) | $(0.24) |
| Cash & Equivalents | $125,358 | $80,532 | $125,358 | $80,532 |
| Total Investments | $102,073 | $98,802 | $102,073 | $98,802 |
| Operating Cash Flow (YTD) | $32,574 | $14,814 | $32,574 | $14,814 |
Liquidity: As of June 30, 2026, the company held $125.4 million in cash and cash equivalents and $102.1 million in investments. The company has a $150 million revolving credit facility with no outstanding borrowings.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22.5% year-over-year (Q2) and 25.9% year-over-year (YTD). This was driven by volume and price growth in MACI and Epicel.
- Profitability: The company returned to profitability in Q2 2026 with net income of $2.2 million, compared to a net loss of $0.6 million in Q2 2025. Operating loss narrowed significantly to $0.4 million from $2.0 million.
- Product Performance:
- MACI: Revenue grew 22.5% (Q2) and 22.2% (YTD), supported by the MACI Arthro launch.
- Epicel: Revenue surged 20.8% (Q2) and 56.8% (YTD) due to higher demand.
- NexoBrid: Revenue increased 32.5% (Q2) and 7.3% (YTD).
- Expenses: Selling, general, and administrative (SG&A) expenses rose 15.7% (Q2) due to sales force expansion and marketing. R&D expenses increased 11.3% (Q2) driven by headcount and the MASCOT ankle trial.
- Cash Flow: Operating cash flow improved significantly to $32.6 million (YTD 2026) from $14.8 million (YTD 2025), aided by strong collections and non-cash stock-based compensation.
Outlook, Risks, and Unusual Items
- Manufacturing Transition: The company is actively transitioning MACI manufacturing to the Burlington facility, which is now FDA-approved for commercial production. This is expected to support future growth and potential international expansion.
- BARDA Agreement: In March 2026, Vericel signed a 10-year agreement with BARDA valued at up to $196.9 million for NexoBrid procurement, inventory management, and development. No revenue was recognized from this agreement in Q2 2026.
- Share Repurchase: In July 2026, the Board authorized a $200 million share repurchase program with no expiration date.
- Risks: Key risks include dependence on third-party payers for reimbursement, supply chain disruptions (specifically for NexoBrid raw materials sourced from Taiwan and manufacturing in Israel), and the success of clinical trials for MACI in the ankle (MASCOT trial).
- Unusual Items: The company recorded a $0.3 million provision for excess and obsolete inventory in the first half of 2026. Stock-based compensation expense decreased slightly year-over-year due to stock price fluctuations.
Investor Verification Checklist
- Reimbursement Rates: Verify the stability of third-party payer reimbursement rates for MACI implants, as revenue is recognized net of estimated contractual allowances.
- Manufacturing Capacity: Confirm the timeline and success of the full transition of MACI production to the Burlington facility to ensure no supply disruptions.
- BARDA Funding: Monitor the drawdown of funds under the BARDA agreement and the specific milestones required for the optional awards.
- Share Repurchase Activity: Track the execution of the new $200 million buyback program and its impact on share count and liquidity.
- Clinical Trial Progress: Review updates on the MASCOT trial for MACI ankle indications, which represents a significant potential market expansion.